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The purpose of ex vivo drug screening in the context of precision oncology is to serve as a
functional diagnostic method for therapy efficacy modeling directly on patient-derived
tumor cells. Here, we report a case study using integrated multiomics ex vivo drug
screening approach to assess therapy efficacy in a rare metastatic squamous cell
carcinoma of the parotid gland. Tumor cells isolated from lymph node metastasis and
distal subcutaneous metastasis were used for imaging-based single-cell resolution drug
screening and reverse-phase protein array-based drug screening assays to inform the
treatment strategy after standard therapeutic options had been exhausted. The drug
targets discovered on the basis of the ex vivomeasured drug efficacy were validated with
histopathology, genomic profiling, and in vitro cell biology methods, and targeted
treatments with durable clinical responses were achieved. These results demonstrate
the use of serial ex vivo drug screening to inform adjuvant therapy options prior to and
during treatment and highlight HER2 as a potential therapy target also in metastatic
squamous cell carcinoma of the salivary glands.
Keywords: ex vivo drug screening, precision oncology, HER2, T-DM1, trastuzumab, molecular profiling, parotid
squamous cell carcinoma
INTRODUCTION
Ex vivo drug screening methods in the context of cancer research collectively refer to high-
throughput screening (HTS) approaches that utilize vital patient-derived tumor cells as models for
assessing drug efficacy. Similarly, as in vitro cell-based high-throughput drug screening, ex vivo drug
screening methods allow assessment of cellular responses to up to thousands of drug perturbations
in a single experiment (1–6). The utility of ex vivo drug screening has been pioneered in the context
of hematological malignancies in which cancer cells can be collected and enriched for HTS directly
from blood or bone marrow biopsies (7–10). These studies have demonstrated that the methods can
be used to complement pathological cancer diagnostic procedures to track patient-specific drug
sensitivity and guide treatment decisions on the most effective treatments or potential alternative
therapies currently approved for other cancer indications. The first clinical trial utilizing ex vivo
chemosensitivity profiling (NCT03096821) to inform treatments of patients with aggressive forms
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of hematological cancers reported an 88% overall response rate
(ORR) in patients matched to treatments on the basis of an ex
vivo drug screening assay (11). By comparison, in recent clinical
trials for genomics matched targeted therapies, the reported
ORRs have varied from 11% to 36% (12–15). This suggests
that the ex vivo drug screening methods could be used to
improve the stratification of targeted cancer treatments and
complement genomic oncology medicine approaches for
personalized care of individual cancer patients. To improve the
feasibility and accuracy of ex vivo drug screening techniques for
solid cancers, especially without the need for invasive surgical
tissue sampling, new assay strategies are needed. As an approach
for diagnostic therapy efficacy testing in solid cancers, we devised
a strategy integrating a phenotypic image-based assay method
(1–4) with reverse-phase protein array (RPPA) drug screening to
analyze patient-specific therapy efficacy for a rare metastatic
parotid squamous cell carcinoma (SCC). Tumor cells isolated
from a disease-affected lymph node were analyzed prior to
treatment initiation and cells isolated from a distal metastatic
lesion were analyzed to adjust treatment strategy after disease
recurrence. Altogether, the efficacy of 193 anti-cancer
compounds was evaluated to establish a comprehensive
chemosensitivity profile. Parotic SCC is a rare, aggressive
salivary gland malignancy to which a consensus regarding the
use of adjuvant chemotherapy does not exist (16). Moreover,
clinical development of novel treatments to this malignancy is
limited by the low number of cases, which limits the use of
conventional clinical study designs. Therefore, alternative
approaches, such as the ex vivo screening, are needed to collect
evidence on the efficacy of alternative targeted treatment




The patient, a 61-year-old male, was identified to the study by an
oncologist at the Jyväskylä Medical Centre (Jyväskylä, Finland).
The tissue biopsies (surgically resected lymph node, sample A
and 3 × 18 gauge needle biopsies, sample B) were collected for
the ex vivo drug screening with written informed consent from
the patient and approval from the local Ethics Committee of the
Central Finland Health Care District (KSSHP 3U/2015). All the
experiments were undertaken with the understanding and
written consent of the patient, and the study methodologies
conformed to the standards set by the Declaration of Helsinki.
Image-Based Ex Vivo Drug Screening
The ex vivo drug screens were performed as previously described
(3). Briefly, the therapeutic compound collection used in the drug
screening consisted of 125 (sample A) and 193 (sample B) anti-
cancer agents, purchased from commercial chemical vendors
(Selleck Biochemical, Santa Cruz Biotechnology). To allow
maximally broad characterization of different drug classes with
the limited number of cells available from the tumor biopsies,
each compound was tested in five different concentrations with
twofold (sample A) and threefold (sample B) dilutions starting from
5 mM as the highest concentration. The single-cell milieu of freshly
isolated tumor-derived cells (45 µl per well; 1,000 cells per well) was
transferred to each well using a peristaltic MultiDrop Combi
dispenser (ThermoScientific). The 384-well plates were incubated
for 96 h in standard cell culture conditions, 37°C and 5% CO2.
Analysis of cell viability with cellular lineage separation was
performed through high-content imaging. The cell cultures were
fixed with 4% paraformaldehyde with 0.03% Triton-X100 and
incubated overnight at +4°C with antibodies against epithelial
cytokeratin-19 (KRT19, Abcam, Clone EP1580Y), stromal cell
marker vimentin (VIM, Santa Cruz Biotechnology, Clone V9),
and HER2 (DAKO, A0485). Secondary antibody staining was
performed at room temperature for 1 h with AlexaFluor
secondary antibodies against the primary host species (1:500,
LifeTech) in 1% BSA. DAPI (4′,6- Diamidino-2-phenylindole
nuclear counterstain, LifeTech) (1 mg/ml) was added to secondary
staining buffers for DNA counterstaining. Cells were imaged using
Olympus scan^R platform at 20× magnification. Nine frames were
acquired from each 384-well to cover the whole well area. Images
were analyzed with Olympus scan^R image analysis suite including
integrated DNA staining-based primary object segmentation using
a watershed algorithm. Primary objects (nuclei) were expanded a
fixed 20-pixel distance, and mean fluorescence signal intensity for
KRT19 and VIM was quantified from this expanded cellular region.
Single-cell positivity for KRT19, VIM, and HER2 was determined
by gating in the scan^R image analysis suite, using secondary
antibody only stained cells for each marker as controls.
Population separated cell count data were normalized using the
GR method (18) (see Equation 1 in Statistical Analysis) to DMSO-
only wells (negative control), 5 µM staurosporin-containing wells
(positive control), and 2 µM aphidicolin-containing wells (cell
growth control). Dose–response curves and growth rate
normalized IC50 estimates were generated in GraphPad Prism
software (V8, GraphPad Software). The ex vivo drug screening
data (Supplementary Figures S1–S3) are deposited to Mendeley
data (DOI: 10.17632/9t7gn926ry.1).
Targeted Genomic Sequencing
The genomic profiling was performed at the Jyväskylä Medical
Centre molecular pathology core (Jyväskylä, Finland). Briefly,
genomic DNA was extracted from the coarse needle tissue biopsy
with QIAamp DNA Mini Kit (Qiagen) according to the protocol
provided by the kit manufacturer . Qiaseq Human
Comprehensive Cancer Panel (Qiagen, DHS-3501Z) including
275 cancer-related genes was used to prepare NGS amplicon
gene library according to the protocol provided by the kit
manufacturer. Unique molecular identifiers (UMIs) were used
to tag individual DNA strands. Sequencing was performed with
Illumina NextSeq500 instrument (Illumina) according to
standard protocol. Data were de-multiplexed and fastq files
were created with bcl2fastq software (Illumina). The data were
processed in CLC Biomedical Genomics Workbench (Qiagen)
with workflow provided by Qiagen and using Hg19 human
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reference genome to call the gene variants. Gene annotations
were performed according to the vcf files in OmnomicsNGS
software (Euformatics, Espoo, Finland). The sequencing data
files are deposited to NCBI Sequence Read Archive (SRA) under
accession no. PRJNA760256.
Immunohistochemistry
Immunohistochemical stainings were performed by following
standard procedures. Shortly, 2-µm FFPE sections were stained
with Bond-III automated IHC stainer (Leica Biosystems) and
Bond Polymer Refine Detection kit (DS9800, Leica Biosystems).
For BLC-2, antigen retrieval was performed with Bond Epitope
Retrieval Solution 2 (AR9640, Leica Biosystems) at 100°C for
20 min. The used antibody dilutions were 1:100 for KRT19
(clone A53-B/A2.26, ThermoScientific), VIM (clone V9,
Novocastra/Leica), and HER2 (clone SP3, ThermoScientific).
Thirty minutes incubation time was used for all antibodies. All
stainings were interpreted by a pathologist.
HER2 Dual ISH Assay
HER2 amplification assay to formalin-fixed paraffin-embedded
sections was done with fully automated Ventana BenchMark Xt
slide stainer (Ventana Medical Systems). Shortly, dinitrophenyl
(DNP)-labeled HER2 probe and digoxigenin-labeled
chromosome 17 (Chr17) probes (INFORM HER2 Dual ISH
DNA Probe Cocktail, Roche) were co-hybridized to their
targets. HER2-DNP probe was visualized with UltraView SISH
DNP detection kit (Roche) using HRP-driven silver
metallographic detection. For Chr17-DIG probe, UltraView
Red ISH DIG detection kit (Roche) was used to produce red
signal in alkaline phosphatase-driven reaction. The copy number
of HER2 was counted from minimum 20 representative nuclei.
HER2 copy number ≥6 was determined as positive for
amplification. If HER2 copy number was uncertain (between 4
and 6), the number of Chr17 centromeres was also counted.
HER2/Chr17 ratios <2 were interpreted as non-amplified and
ratios ≥2 were interpreted as amplified.
RPPA, Quantitation, and Analysis
For the RPPA, screening cells (1,000 per well) were treated in
384-microplate wells with 19 drugs in five concentrations with
twofold dilutions starting from 5 µM as the highest
concentration. Lysates were collected at the 48-h time point
after drug treatment. To generate reverse-phase arrays, lysates
were printed on nitrocellulose-coated glass slides (Grace Biolabs
#305177) on a Genetix QArray Mini Arrayer (Molecular
Devices). Primary antibodies used for RPPA experiments
contained the following: p-AKT (Ser473) (Cell Signaling
Technology Cat# 4060), AKT (Cell Signaling Technology Cat#
4691), p-ERK1/2 (Thr202/Tyr204) (Cell Signaling Technology
Cat# 4370), p-S6 Ribosomal protein (Ser235/236) (Cell Signaling
Technology Cat# 2211), Ki-67 (Abcam Cat# ab15580), HER2
(DAKO Cat# A0485), p-HER2 (Y1248) (R&D Systems Cat#
AF1768), and p-cMET (Tyr1234/1235) (Cell Signaling
Technology Cat# 3129). Secondary detection was performed
with a goat anti-mouse IgG conjugated to DyLight 680
(Thermo Pierce Cat# 35518) and goat anti-rabbit IgG
conjugated to DyLight 800 (Thermo Pierce Cat# 35571)
antibodies. For total protein measurement, the arrays were
stained with a Sypro Ruby Blot solution (Invitrogen) and an
antibody for actin (Cell Signaling Technology Cat# 4970). The
slides were scanned with a Tecan LSReloaded (Tecan)
microarray scanner to detect the Sypro signals and Odyssey
Licor IR‐scanner (LI‐COR Biosciences) to detect the antibody
signals. Array‐Pro Analyzer microarray analysis software (V6.3
Media Cybernetics) was used for analyzing the data. Antibody
signals were normalized to the Sypro total protein, log
transformed, and z‐score standardized. z‐scores < −2.0 or >2.0
(−/+ 2×standard deviation from the whole screen) were
considered as significantly downregulated or upregulated,
respectively. Box plots, heatmaps, and Pearson correlation
analyses were created on GraphPad Prism software.
Flow Cytometry
MISB10 cells cultured in T75 flasks were treated with Accutase
(BD Biosciences) and washed twice with PBS with 1% BSA.
Suspensions were counted and measured for cell viability using
the Vi-Cell XR cell counting and viability analyzer (Beckman
Coulter). Cells were diluted in PBS to 1 × 106 cells/ml and stained
for 30 min at RT with membrane viability dye (LIVE/DEAD
Fixable Near-IR, Invitrogen). Cells were washed and distributed to
a 96-well plate containing staining antibodies and Hoechst 33342
(Invitrogen). For characterization panels, immunophenotyping
antibodies to the following targets were used: HER-2/neu, CD24,
CD29, CD44, CD45, CD49f, CD90, CD166, CD326 (BD
Biosciences), and CD133 (Miltenyi Biotec, Auburn, CA). Cells
were incubated for 30 min at RT in the dark and then rinsed twice
in PBS before acquisition with a BD LSRII flow cytometer.
Analysis of results was performed using FACSDiva v6.1.3 and
FlowJo analysis software (FlowJo).
MISB10 Cell Line
Approval to use the cells for culture and in vitro research was
obtained from the patient and the local ethical committee prior
to the study. The tumor tissue-derived cells were grown for 4
months in RPMI-1640 culture media supplemented with
penicillin/streptomycin (100 units/100 mg), l-glutamine
(2 mmol/L), fetal bovine serum (5%, Biowest), and 1× ITS-G
(Insulin-Transferrin-Selenium, Gibco). The resulting cell line,
designated MISB10, grew continuously when the culture
medium was changed twice per week. Confluent cultures were
dissociated for 2 min at +37°C using TrypLE Select enzyme
(Gibco), and split into new cultures with ratios of 1:2 or 1:3.
Cryopreservation was done in CellVation (MP Biomedicals)
cryopreservation media. The MISB10 cell line will be available
for non-profit research purposes through the corresponding
author on reasonable request and in accordance to a
specified MTA.
Statistical Analysis
The ex vivo drug screening data were analyzed using the
normalized growth rate inhibition (GR) approach, which yields
per-division metrics for drug potency and efficacy. The GR
values were calculated from the raw image cytometry cell
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count data with no plate normalization or other data pre-
processing and used for comparison of drug potency between
the epithelial and stromal sub-cell populations having a
differential proliferation rate during the screening. GR values
were calculated using:
– x(c), the cell count value of a cell population per well following
drug treatment at concentration c.
– xctrl, the average cell count value of a cell population in DMSO-
treated control wells from the same plate; xctrl = mean({xi∈x |
abs(log10(xi)–log10(mean(x)))o1.5)}), where x are all DMSO-
treated control values.
– x0, the average cell count value of a cell population in 2 µM
aphidicolin-treated control wells from the same plate;
x0 = mean({xi∈x | abs(log10(xi)–log10(mean(x))) o1}),
where x is the vector of treated values.
Supplementary Data 1, 2 comprise the GR values for each
treated condition of the KRT19+, VIM+, and HER2+ cell









Welch’s t-test, Student’s t-test, and Pearson correlation analyses
as indicated in the figure legends were applied using GraphPad
Prism V8 software according to assumptions on data normality.
RESULTS
Ex Vivo Drug Screen on Lymph Node
Metastasis-Derived Tumor Cells
Our patient, a 61-year-old male, originally presented with facial
nerve paresis and expansive mass in neck 3 years earlier to the
study. Primary diagnostic studies revealed a mass in his left
parotid gland. Following a lung CT, a radical parotidectomy and
dissection of neck lymph nodes to regions I–V was performed.
Histopathological diagnosis was poorly differentiated squamous
cell cancer of the parotid gland and post-operative PET-CT scan
revealed multiple lung metastases and residual activity in the
tumor bed area. Treatment of the disease was initiated with
cisplatin–5-fluorouracil chemotherapy regimen to reduce tumor
burden. After two cycles of chemotherapy, concurrent
chemoradiation therapy with weekly cisplatin was initiated and
completed to 50 Gy dose to the residual tumor operation bed and
left neck lymph node areas. Local control of the disease was
achieved, but lung metastases remained, and residual lung
lesions were considered inoperable. Following a 3-month
treatment holiday, chemotherapy was changed to nab-
paclitaxel (Abraxane). CT scan for response evaluation showed
stable disease after 4 months. Response evaluation at 12 months
showed progressive disease. At this time, as per discussion with
the patient and with approval from the local Ethics Committee of
the Central Finland Health Care District, a lymph node sample
was retrieved from the left axilla area and processed for the ex
vivo screening under written informed consent by the patient.
The node was cut in half and one-half was processed for routine
histopathology. The inner mass of the other half was drained
from excess immune cells, cut into small fragments, and
disaggregated enzymatically to achieve a single cell milieu of
cells (1) (Figure 1A). The resulting cell suspension was diluted
into cell culture medium and dispensed immediately onto drug
containing 384-microwell plates (Supplementary Figure S1).
Following 96-h exposure of the cells to 125 drugs in five
concentrations, high-content imaging cytometry with
immunofluorescent antibody staining of the cells with
cytokeratin-19 (KRT19) as epithelial (19) and vimentin (VIM)
as stromal (1, 3) cell marker was used to quantify the cell-type-
specific drug efficacy (Supplementary Figure S1A). Dose
responses were compared to the negative and positive assay
controls to normalize the dose responses of the two cell
populations separately to the measured growth rate (3, 18) of
each population as described in Equation 1; 77.1% of all analyzed
cells were KRT19+ and 19.5% were VIM+. The calculated cell
doubling rate of the KRT19+ cells was ~220 h and ~135 h for the
VIM+ cells, corresponding to 0.44 and 0.77 cell divisions over the
course of the 96-h assay, respectively (18) (Supplementary
Figure S1B). To identify the most potent tumor cell-targeted
cytotoxic drugs, we compared the GR-corrected IC50 estimates of
the drugs between the KRT19+ and VIM+ cells (Figure 1C and
Supplementary Figure S2A). Topoisomerase inhibitors, HDAC
inhibitors, alkaloid and taxane tubulin poisons, CDK inhibitor
dinaciclib, and TKi dasatinib were collectively the most cytotoxic
drugs on both cell types with an average IC50 below 1 µM
(Figure 1B and Supplementary Figure S2B). Twenty-two drugs
had a selective cytotoxic effect only on the KRT19+ cells
(Figure 1C). The EGFR-TKis afatinib, erlotinib, and neratinib,
AKT-HER2 inhibitor lapatinib, and c-METi crizotinib were the
most potent drugs with a selective cytotoxic effect only on the
KRT19+ cells (Figures 1B–D).
Ex Vivo Informed Treatment
Based on the ex vivo drug screening results, the patient’s tumor
cells were selectively most sensitive to EGFR/HER2 inhibitors as
a class of drugs. Amplifications, high expression levels, and
genomic aberrations of HER2 have been reported frequent in a
subset of salivary duct carcinomas (17, 20) and several case
studies using EGFR/HER2-TKi therapies including cetuximab,
erlotinib, gefitinib, T-DM1, and trastuzumab on individual
salivary gland cancer patients have been reported. However, at
the time of diagnosis of the metastatic disease, checking HER2
status was not considered standard clinical practice in parotid
carcinoma in Finland. To assess whether our patient’s tumor
cells’ sensitivity to the EGFR/HER2 inhibitors was due to
possible amplification of HER2, additional histopathological
analysis including HER2 immunohistochemistry and dual ISH
HER2 amplification assay was performed on the lymph node
tissue from which the sample cells to the ex vivo assay were
isolated. Immunohistochemistry results indicated complete,
strong, membranous staining, compatible with 3+ HER2
(ASCO/CAP HER2 expression criteria) (Figure 2A)
accompanied with a copy number gain confirmed with CISH
analysis. Based on the ex vivo drug screening result, the
Nykänen et al. Ex Vivo Therapy Efficacy Modeling




FIGURE 1 | Ex vivo drug screening in metastatic parotid duct carcinoma. (A) Schematic presentation of the study strategy. (B) Gallery view of representative 20×
immunofluorescence microscopy images of the sample cells treated for 96 h with the indicated drugs in five different concentrations (nM). KRT19 staining shown in
red and VIM staining in green. Bars: 50 µm. (C) Scatter plot showing correlation of the mean GR score of 125 drugs in five doses for the KRT19+ and VIM+ cells.
(D) EGFR-TKis were identified as drugs with a selective cytotoxic effect on the KRT19+ cells. Box plots showing the GR scores for the five doses of all EGFR-TKi
included in the screen and compared using paired Student’s t-test.
A
B
FIGURE 2 | Validation of HER2 status and targeted therapy. (A) Immunohistochemistry validation of HER2 staining in the affected lymph node. Scale bars: 2.5 mm,
250 µm, and 100 µm (left to right). (B) Radiologic response of patient. Left, prior to treatment, and right, after four cycles of treatment with T-DM1.
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immunohistochemistry confirmation and an earlier case report
describing sustained clinical response of two HER2+ metastatic
salivary gland cancer to ado-trastuzumab emtansine (T-DM1)
(21, 22), the patient was considered for treatment with T-DM1.
In Finland, HER2-directed therapies are still not reimbursed or
generally available for salivary gland cancers. However, after
clinical evaluation, treatment with T-DM1 was initiated with off-
label use. After 4 months and four cycles of T-DM1, a partial
response was confirmed with radiographic examination
(Figure 2B). The patient was asymptomatic and tolerated the
treatment well. After 6 months, the lung and lymph node lesions
continued to shrink. Systemic treatment with T-DM1 was
continued, and at 10 months of therapy, lung lesions remained
stable, but a new 4-cm tumor lesion had appeared between the
sixth and seventh rib and the lumbar spine (L1). A new biopsy
sample for repeated ex vivo analysis was then retrieved from the
lesion between the ribs (Supplementary Figure S3).
Repeat Analysis of Drug Efficacy in
Recurrent Disease
To evaluate drug sensitivity of the new metastatic lesion and the
recurrent disease, a repeat ex vivo drug screening was undertaken
with cells isolated from the new lesion. A parallel tissue biopsy from
the same lesion was subjected to targeted DNA sequencing. The
image-based assay strategy as used with sample A was used again
with staining of HER2 as a thirdmarker for detection of HER2+ cells
(Figure 3D). Efficacy of 193 drugs in five doses was compared
between the VIM+, KRT19+, and HER2+ cells (Supplementary
Figures S1 and S4A). One hundred percent of the KRT19+ cells
were also HER2+ (without treatments), and similarly as in sample A
analysis, the EGFR-TKis afatinib and neratinib were among the
most potent drugs with a selective cytotoxic effect on the KRT19+
cells (Figures 3A, B). However, the cytotoxic effect of EGFR/HER2
targeted drugs erlotinib and lapatinib, as well as mTOR inhibitors
everolimus and rapamycin varied significantly between samples A
and B (Figure 3C and Supplementary Figures S4B, C). MTOR
inhibitors AZD2014 and AZD8055, and PI3K inhibitors Buparlisib
and AZD8835, on the other hand, showed higher efficacy in sample
B (Supplementary Figures S4B, C).
To analyze the pathway inhibition efficacy of the most potent
identified targeted inhibitors on downstream targets of the
HER2/PI3K/AKT/mTOR and EGFR/RAS/MEK pathways, we
performed a RPPA screen with the patient-derived cells. In the
RPPA experiment, the cells were exposed for 48 h to 16 drugs
selected from the ex vivo screen including all the EGFR-TKis and
trastuzumab, T-DM1 (Kadcyla), and sapitinib (pan-EGFRi) as
additional EGFR-TKis. Drugs were tested in five doses with
twofold dilutions and eight markers; phospo-S6RPS235/236,
HER2, phospho-HER2Y1248, AKT, phospho-AKTS473, phospho-
ERK1/2T202/Y204, phospho-METY1234/1235, and Ki-67 were used
as the assay readout (Figure 4A). Analysis of the RPPA data
(Supplementary Figure S5A) indicated strongest correlation
between the proliferation of the cells (z-score Ki-67) and
p.HER2 (Pearson correlation, r = .43), p.S6R (r = .48), and
p.ERK1/2 (r = .68) (Figure 4A). EGFR-TKis including afatinib,
sapitinib, and T-DM1 effectively blocked all of these markers,
while the dual MTORC1/2 inhibitor AZD2014 (vistusertib) had
the strongest dose-dependent effect on MTORC1/2 downstream
effectors AKT and S6RP (Supplementary Figure S5B).
Supported by the RPPA results and the image-based screen
results indicating that the HER2 expression was amplified in a
dose-dependent manner by lapatinib and downregulated by the
A B D
C
FIGURE 3 | Repeat ex vivo drug screen in recurrent disease. (A) Scatter plot showing correlation of the mean GR score of 193 drugs in five doses for the HER2+
and VIM+ cells. (B) Scatter plot showing correlation of the IC50 estimate of the analyzed drugs between the HER2
+ sample B cells and KRT19+ sample A cells.
(C) Box plots showing the GR scores for the five doses of afatinib, neratinib, erlotinib, and lapatinib in sample A and B KRT19+ and HER+ cells. Afatinib and neratinib
displayed a statistically significant differential effect on the KRT19+ and HER+ cells from sample B as compared using paired Student’s t-test. (D) Gallery view of
representative 20× immunofluorescence microscopy images of the sample cells treated for 96 h with the different EGFR-TKis in five different concentrations (nM).
KRT19 staining shown in blue, VIM staining in green and HER2 staining in red. Bars: 50 µm.
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EGFR-TKis (Figure 4B and Supplementary Figure S5A), we
rationalized that combination of lapatinib could potentiate the
overall therapeutic efficacy of the EGFR-TKis as reported in
several human cancers (23–25). We explored the effect of
combining the highest-ranking EGFR-TKi afatinib with
lapatinib to evaluate synergy between the two drugs. Three
different drug combination schemes were compared with a
fixed 1:5 molar ratio of the drugs (afatinib IC50 1.64 µM,
lapatinib IC50 7.19): (1) 72-h simultaneous treatment, (2) 24-h
lapatinib pre-treatment followed with 48 h addition of afatinib,
and (3) 24-h afatinib pre-treatment followed with 48 h addition
of lapatinib (Figure 4C). The combinations resulted in
significant synergistic effects across all three treatment
schedules with a mean CI50 combination index (26) of 0.47
with the simultaneous treatment, 0.15 with lapatinib pre-
treatment, and 0.86 with afatinib pre-treatment (Figure 4C).
The impact of the drug combination on HER2 protein level
expression and phosphorylation of AKT was also confirmed with
a Western blot analysis from the cells (Figure 4D). However, the
synergistic effect was significantly more potent with lapatinib
being administered first in comparison to simultaneous or
reversed administration (p <.0001 both) (Figure 4C),
suggesting that the order of administration of the two drugs
could affect the overall combination efficacy.
Treatment of the Recurrent Disease
The targeted DNA sequencing performed from sample B
identified a p53 p.R273C (allele frequency 69%) mutation, a
CHEK2 p.I157T (freq. 40%) mutation, and a HER2 p.V747L
mutation (freq. 93%), while HER2 CISH assay confirmed a
HER2 copy number gain. Following relapse of the disease after
treatment with T-DM1, the patient’s treatment was continued
with capecitabine as a single agent. After 2 months, the patient
suffered a seizure and multiple brain metastases were detected in
MRI. These lesions were not suitable for stereotactic
radiotherapy and the patient received palliative whole-brain
radiotherapy. The patient was then considered for a second
cycle of experimental therapy based on the ex vivo drug
screening and molecular pathology results. As the ex vivo





FIGURE 4 | A pathway perspective on targeted therapy responses. (A) Heat map visualization with one-dimensional (vertical) unsupervised clustering of the z-
scores of the eight RPPA markers across 19 drugs in five concentrations (left to right, low to high, respectively). (B) Top: Representative microscope images of HER2
staining on sample B cells in the ex vivo screen following 96-h exposure to the indicated drugs at 5 µM concentration. KRT19 staining shown in blue, VIM staining in
green, and HER2 staining in red. Bars: 50 µm. Bottom left: Box plot showing the mean and standard deviation of fluorescence intensity of HER2 staining (RFU) of
the KRT19+ cells in response to treatment with the different EGFR-TKis. Two biological replicate experiments were combined and compared using unpaired Welch’s
t-test. Bottom right: Comparison of the HER2 staining intensity to DMSO-treated cells. Signal shown as fold change. (C) Combination of lapatinib and afatanib
shows a synergistic growth inhibitory effect. With all three different drug schedules tested, the combination resulted in significantly increased efficacy over the single
agents as indicated by the lower IC50 (middle panel). On the basis of the CI50 combination index, lapatinib pre-treatment preceding afatinib treatment had the highest
synergy (right panel). Comparison was made using unpaired Student’s t-test. (D) The patient-derived tumor cells were treated with DMSO (−), 1000 nmol/L afatinib,
lapatinib, neratinib, or combination of 1000 nmol/L afatinib+lapatinib, or neratinib+lapatinib for 48 h, and phosphorylation (p) AKT and total HER2 protein levels of
indicated markers were assessed using Western blot. Actin was assessed as a loading control.
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to respond to EGRF-TKis and that lapatinib potentiated these
effects, trastuzumab–lapatinib regimen was initiated (27, 28)
with five daily doses of lapatinib as a pre-treatment. Control
CT scan performed after two cycles of trastuzumab and daily
dosing of lapatinib showed that the lung metastases had
remained stable. The soft tissue tumor component of the
metastasis between the sixth and seventh rib had been
completely resolved with only a sclerotic bony lesion
remaining while the lytic, metabolically active metastatic lesion
on the lumbar spine (L1) had been stabilized (Figure 5). The
trastuzumab–lapatinib regimen was continued as therapy for 10
months until clear progressive disease was observed, and the
patient started to receive the best palliative care. The patient
succumbed to the disease 26 months after the initial ex vivo
sample was obtained and 60 months from the primary diagnosis.
A New HER2+ Parotid Carcinoma Model
Cell Line
Many of the defined molecular subtypes of salivary gland
malignancies represent a HER2+ molecular background (20),
yet no HER2+ model cell lines have been described, and only two
salivary gland cancer-derived model cell lines are altogether
included in the CCLE collection of 1,739 human cancer cell
lines (29). The patient-derived cells left over from the performed
ex vivo analyses of sample B were kept in culture in standard cell
culture conditions after the patient was started treatment with
the trastuzumab–lapatinib regimen. After 4 months in culture,
the cells started to show stable in vitro growth and a uniform
morphology with no residual stromal cell contamination
growing in the culture. The cells grew continuously as an
adherent monolayer (Figure 6B) and reached confluence in 4
to 6 days with 1:3 ratio passaging in 10-cm culture dishes. After
the cells had undergone ~20 passages, a comprehensive flow
cytometry immunoprofiling was performed to establish an
immunophenotypic profile of the cells and to assess clonal
heterogeneity of the culture. Over 99% of the cells were found
to be EpCAM+ with >98% being HER2+, CD24+, CD44+, CD29+,
CD49f+, CD90-, and CD184- (29) (Figure 6A). In addition to
these epithelial cell lineage markers, the EpCAM+ cells were also
found to express CD47, a potential immune evasion marker (30),
CD54 (31), CD64, CD73 (32), CD151, and c-MET (Figure 6C),
which could explain the cells’ responsiveness to the c-METi
crizotinib (Figure 1B and Supplementary Figure S2B).
Currently, subcultures of the cells devoted a cell line named
MISB10, which have undergone an excess of 80 passages; they
show continuous growth and can recover from repeated
cryopreservation cycles; they show responsiveness to EGFR-
TKi targeted therapies and form multicellular organotypic
spheroids while grown in human tumor microenvironment
mimicking 3D culture conditions (33) (Supplementary
Figure S6).
DISCUSSION
Parotid squamous cell carcinoma is a rare, aggressive salivary
gland malignancy, which often presents at an advanced stage
with nodal metastases. While most salivary gland tumors in
A
B
FIGURE 5 | Clinical response to dual inhibitor lapatinib (AKTi)–trastuzumab (HER2i) therapy. (A) Following 2 months of treatment, the soft tissue component of the
metastasis lesion between the sixth and seventh rib was completely resolved. (B) The lytic lumbar spine (L1) lesion was stabilized following 2 months of treatment.
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general are benign in nature, this tumor is highly aggressive and
approximately 65% of patients die from progressive disease
within 48 months (34). There are no standard treatment
options for recurrent and metastatic disease, and the role of
adjuvant chemotherapy on overall survival is not known due to
the very low incidence rate. Surgical resection followed by
radiation therapy thus remains the main management strategy
for parotid squamous cell carcinomas with limited other
therapeutic options for metastatic disease. While up to 44% of
parotid duct carcinomas have been reported to have HER2
amplifications or high protein or mRNA level expression of
HER2 (20, 35), the number of HER2-positive parotid SCC cases
is lower (36). This suggests that while less frequent in parotid
SCC than parotic duct carcinomas, HER2 aberrations represent a
significant target, biomarker, and opportunity for targeted
treatment also in a subset of patients with parotid SCC tumors
(17, 20, 33, 37). To improve outcomes and efficacy of treatment
of primary and/or metastatic parotid SCC, systematic studies
involving larger series of HER2+ salivary gland cancers or
stratification of patients to HER2-targeted therapies by
alternative strategies are needed to determine the contribution
of HER2 targeting on tumor response outcomes in parotid SCC
and other salivary gland cancers (17).
In this study, we identified the sensitivity and HER2 positivity
of the patient’s cancer on the basis of drug sensitivity of the vital
tumor cells to EGFR-TKi in an ex vivo drug screen. At time of the
study, analysis of HER2 status was not considered standard
clinical practice in parotid carcinoma in Finland. This shows
that ex vivo drug screening can be used as a platform to
complement molecular pathology information and quickly
identify actionable drug sensitivities that can be matched with
the molecular characteristics of the patient’s tumor and thus
motivate personalized medicine. By identifying the response of
the patient-derived tumor cells to the EGFR-TKis, our results
helped to guide our patient’s treatment to include treatment
options that are currently still not generally available for these
patients, but which resulted in sustained clinical benefit. Molecular
profiling of the patient’s tumor also identified a novel HER2
mutation affecting the protein tyrosine kinase domain and a
CHEK2 mutation previously identified as a cancer susceptibility
gene in the Finnish population (38, 39). As HER2mutations have
been shown to reduce the efficacy of therapies commonly used to
A
B C
FIGURE 6 | Flow cytometry immunophenotyping of the MISB10B cells. (A) Analysis of expression of epithelial lineage markers and HER2 in the EpCAM+ cells.
(B) Representative bright-field microscopy image (10×) of the morphology of the MISB10B cells in near full confluent state. (C) Analysis of expression of additional
immunophenotypic markers in the EpCAM+ cells.
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treat HER2-positive breast cancer, particularly in metastatic and
previously HER2 inhibitor-treated patients (40), our data, even
though limited by being an analysis only of one patient, provide
novel insights into general and EGFR-TKi-specific drug efficacy in
cancers bearing these aberrations. For further analyses of these
aspects, the MISB10 cell established from the patient’s tumor
represents a unique new in vitro research resource as the first and
only described HER2-amplified, HER2 mutant salivary gland
cancer cell line in the world (41).
In summary, we present here the first large-scale ex vivo drug
screening in a metastatic parotid squamous cell carcinoma
together with use of HER2-targeted therapies adding one more
case example to the existing medical literature supporting the use
of HER2-directed therapies for a subset of salivary gland tumors.
Since parotic SCC is a rare tumor type, it is difficult to conduct
prospective clinical studies to compare which of the existing
HER2 directed agents is the most effective, but this case example
suggests that antibody–chemotherapy conjugates seem to have
promising activity. Future studies should also investigate
trastuzumab–deruxtecan for this patient population as,
currently, there are no adjuvant treatment options that affect
the overall survival of metastatic parotid SCC patients (42). New
treatment modalities are therefore urgently needed to improve
the outcome of this aggressive disease.
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